Ketotifen Unit Dose Stulln (Ketotifen)

Ketotifen blocks H1 histamine receptors on ocular tissues, preventing histamine‑induced itching and vasodilation. It also stabilizes mast cells, reducing the release of inflammatory mediators such as leukotrienes and prostaglandins, which together diminish ocular allergic inflammation.

The appropriate dose of Ketotifen Unit Dose Stulln is determined by the prescribing eye‑care professional based on the severity of symptoms and patient factors. Patients should follow the prescriber’s instructions and the product label for administration.

Safety data for ketotifen in pregnancy and lactation are limited. It should only be used if the prescriber judges that the potential benefit outweighs any possible risk to the fetus or infant. Women who are pregnant or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Ketotifen combines H1‑receptor antagonism with mast‑cell stabilization, offering both immediate symptom relief and longer‑term control of ocular inflammation. Some alternatives act only as H1 blockers and may not provide the same mast‑cell stabilizing effect, potentially requiring more frequent dosing for comparable control.

Ketotifen Unit Dose Stulln should be stored at room temperature, below 25 °C, in its original packaging. Protect the unit‑dose containers from moisture, direct sunlight and extreme temperatures to maintain product stability.

The product is supplied as a unit‑dose ocular preparation. The patient should instill a single drop into the affected eye(s) as directed by the prescriber, typically one to two times daily, and avoid touching the tip of the container to the eye or surrounding tissues.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, corneal ulceration, persistent eye pain, sudden vision loss, and significant intra‑ocular pressure elevation. Patients should seek immediate medical attention if they experience any of these symptoms.

Individuals with a known hypersensitivity to ketotifen or any component of the formulation should avoid using the product. It is also contraindicated in eyes with active infection until the infection is resolved, and should be used with caution in patients with uncontrolled glaucoma.